drugset / Trial / NCT00002230

A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients

NCT00002230

Phase 3 Completed 100 enrolled Northwestern University
Treatment

Summary

To determine the virologic benefits associated with the addition of hydroxyurea (HU) to combination drug therapy with didanosine (ddI), stavudine (d4T), and efavirenz (DMP) in HIV-infected patients. To assess the safety and tolerance of this regimen, with or without HU.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxyurea Other / unclassified
Background Didanosine Small molecule
Background Efavirenz Other / unclassified
Background Stavudine Other / unclassified